Literature DB >> 10340557

Vasculitic peripheral ulcerative keratitis.

E M Messmer1, C S Foster.   

Abstract

The onset of peripheral ulcerative keratitis in the course of a connective tissue disorder, such as rheumatoid arthritis, relapsing polychondritis, or systemic lupus erythematosus, may reflect the presence of potentially lethal systemic vasculitis. Moreover, peripheral ulcerative keratitis may be the first sign of systemic necrotizing vasculitis in patients with Wegener's granulomatosis, polyarteritis nodosa, microscopic polyangiitis, or Churg-Strauss syndrome. Although the exact pathogenesis of this severe corneal inflammation and destruction is not well understood, evidence points to a dysfunction in immunoregulation with immune complexes formed in response to autoantigens or to some unknown microbial antigen depositing in scleral and limbal vessels. These events lead to changes that are mainly responsible for the resulting tissue damage. In pauci-immune vasculitides positive for antineutrophil cytoplasmic antibodies, cell-mediated cytotoxicity may play an important role in the pathogenesis of peripheral ulcerative keratitis. Untreated systemic conditions such as those mentioned above may carry a grave prognosis for the eye and may also be life-threatening. Immunosuppressive therapy with corticosteroids and cytotoxic agents is, we believe, mandatory in the treatment of these multisystem disorders associated with vasculitic peripheral ulcerative keratitis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10340557     DOI: 10.1016/s0039-6257(98)00051-4

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  38 in total

1.  Bilateral Mooren's ulcer in a child secondary to helminthic infestation of the gastrointestinal tract.

Authors:  Prakashchand Agarwal; Digvijay Singh; Gautam Sinha; Namrata Sharma; Jeewan Singh Titiyal
Journal:  Int Ophthalmol       Date:  2012-06-03       Impact factor: 2.031

2.  Bilateral Mooren's ulcer in six patients: diagnosis, surgery and histopathology.

Authors:  Christos D Kalogeropoulos; Vassiliki D Malamou-Mitsi; Miltiadis B Aspiotis; Konstantinos G Psilas
Journal:  Int Ophthalmol       Date:  2004-01       Impact factor: 2.031

3.  Sclerokeratitis in Takayasu's arteritis: a case report.

Authors:  Sudesh K Arya; Rajni Nahar; Subina Narang; Rajeev Jain; Naveen Kalra; Sunandan Sood
Journal:  Jpn J Ophthalmol       Date:  2005 Nov-Dec       Impact factor: 2.447

4.  Corneal melt secondary to eosinophilic granulomatosis with polyangiitis.

Authors:  Evelyn Fennelly; Emily Greenan; Conor C Murphy
Journal:  BMJ Case Rep       Date:  2019-06-21

5.  Peripheral ulcerative keratitis as the presenting feature of systemic rheumatoid vasculitis without joint involvement.

Authors:  Peter J Morgan-Warren; Simon Dulku; Jaya Ravindran; George Smith
Journal:  Int Ophthalmol       Date:  2014-08       Impact factor: 2.031

Review 6.  Eye manifestations in patients with perinuclear antineutrophil cytoplasmic antibody-associated vasculitis: case series and literature review.

Authors:  Toshihiko Matsuo
Journal:  Jpn J Ophthalmol       Date:  2007-04-06       Impact factor: 2.447

Review 7.  Inflammatory conditions of the eye associated with rheumatic diseases.

Authors:  N A Afshari; M A Afshari; C S Foster
Journal:  Curr Rheumatol Rep       Date:  2001-10       Impact factor: 4.592

Review 8.  Ocular inflammatory diseases associated with rheumatoid arthritis.

Authors:  Mathieu Artifoni; Pierre-Raphaël Rothschild; Antoine Brézin; Loïc Guillevin; Xavier Puéchal
Journal:  Nat Rev Rheumatol       Date:  2013-12-10       Impact factor: 20.543

Review 9.  Granulomatosis with polyangiitis (Wegener's disease): An updated review of ocular disease manifestations.

Authors:  Buraa Kubaisi; Khawla Abu Samra; C Stephen Foster
Journal:  Intractable Rare Dis Res       Date:  2016-05

Review 10.  Scleritis and peripheral ulcerative keratitis.

Authors:  Anat Galor; Jennifer E Thorne
Journal:  Rheum Dis Clin North Am       Date:  2007-11       Impact factor: 2.670

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.